Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Resistance to BRAF inhibitors is an emerging problem in the melanoma field. Strategies to prevent and overcome resistance are urgently required. METHODS: The dynamics of cell signalling, BrdU incorporation and cell-cycle entry after BRAF inhibition was measured using flow cytometry and western blot. The ability of combined BRAF/MEK inhibition to prevent the emergence of resistance was demonstrated by apoptosis and colony formation assays and in 3D organotypic cell culture. RESULTS: BRAF inhibition led to a rapid recovery of phospho-ERK (pERK) signalling. Although most of the cells remained growth arrested in the presence of drug, a minor population of cells retained their proliferative potential and escaped from BRAF inhibitor therapy. A function for the rebound pERK signalling in therapy escape was demonstrated by the ability of combined BRAF/MEK inhibition to enhance the levels of apoptosis and abrogate the onset of resistance. CONCLUSION: Combined BRAF/MEK inhibition may be one strategy to prevent the emergence of drug resistance in BRAF-V600E-mutated melanomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“…UK Keywords: melanoma; BRAF; resistance; therapy The discovery that B50% of human melanomas harbour activating V600E mutations in the serine/threonine kinase BRAF has raised the possibility that these tumours may be amenable to targeted therapy (Davies et al, 2002; Smalley and Flaherty, 2009).”
BackgroundDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · cited 2×
“Of these, PLX4032 and PLX4720 (Plexxikon/Roche, Nutley, NJ, USA), have been exciting great interest, with recent studies from our group and others showing these compounds to have excellent anti-tumour activity in vitro and in vivo (Cartlidge et al, 2008; Sala et al, 2008; Tsai et al, 2008).”
BackgroundSelf-citationThe RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228 · cited 3×
“There is already evidence that both ARAF and CRAF affect pathways other than MEK, and although not well characterised, it is possible that other BRAF targets may exist (”
BackgroundSawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165 · cited 1×
“These observations mirror the pattern of response seen to targeted therapy in CML, GIST (Sawyers, 2004; Bauer et al, 2007) and most recently medulloblastoma (Rudin et al, 2009; Yauch et al, 2009), where an initial period of tumour regression is later followed by relapse.”
ResultTreatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Yauch, R. L., Dijkgraaf, G. J. P., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C. A., Tang, T., et al. (2009) · Science · doi:10.1126/science.1179386 · Cited by 839 · cited 1×
“These observations mirror the pattern of response seen to targeted therapy in CML, GIST (Sawyers, 2004; Bauer et al, 2007) and most recently medulloblastoma (Rudin et al, 2009; Yauch et al, 2009), where an initial period of tumour regression is later followed by relapse.”
ResultMEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633 · cited 8×
“Earlier studies have suggested that acquired resistance to the MEK inhibitor AZD6244 occurs as the result of an acquired mutation in MEK1 (Emery et al, 2009).”
BackgroundMethodInfluentialPratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614 · cited 2×
“Although targeting the same pathway at two points seems redundant, it is likely that dual inhibition may be a good strategy to counteract the feedback inhibition loops that are relieved after pathway blockade at a single point (Pratilas et al, 2009).”
BackgroundElevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508 · cited 4×
“There is already evidence that both ARAF and CRAF affect pathways other than MEK, and although not well characterised, it is possible that other BRAF targets may exist (Wellbrock et al, 2004a).”
BackgroundInfluentialSmalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463 · cited 2×
“Cells were seeded in 10 cm plates at a density of 100 000 cells ml 1 and grown overnight before being treated with PLX4720 (3 mM) for 72 h or 1, 2, 3 and 4 weeks.”
MethodSelf-citation
Cited by
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
“Vomiting 0 8 (15) 2 (4) 23 (43) 1 (2) 22 (40)”
Self-citationCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Self-citationTsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
“Of note, at this prolonged treatment time point, pERK levels rebounded likely due to feedback mechanisms that have previously been observed to begin within a few days during MAPK inhibition (Figure S7B) (Lito et al., 2012; Paraiso et al., 2010).”
BackgroundSelf-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“408 The combination of RAFi together with other down-stream inhibitors (e.g., MEK inhibitors) can maximize MAPK pathway inhibition and minimize cancer resistance.”
BackgroundVemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Metadata
- Authors
- Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M.
- Affiliations
- Moffitt Cancer Center (US)
- University of South Florida (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Smalley, K S M
- Venue
- British Journal of Cancer
- Published
- 2010-06
- Volume
- 102
- Issue
- 12
- Pages
- 1724-1730
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2883709
- OpenAlex
- W1970039331
- Semantic Scholar
- 902519b5b657cc83ab817259ebcc30d016a6a89a
- Cited by
- 314
- References
- 29
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 10 · 2023: 19 · 2022: 12 · 2021: 15 · 2020: 13 · 2019: 16 · 2018: 19 · 2017: 22 · 2016: 16 · 2015: 22 · 2014: 34 · 2013: 28 · 2012: 40
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- American Cancer Society (93-032-13)
- Melanoma Research Foundation
- Melanoma Research Alliance
- Moffitt Cancer Center
- Plexxikon
- National Institutes of Health
- National Cancer Institute (U54CA143970)
- State of Florida
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- melanoma, BRAF inhibitor resistance, BRAF V600E mutation, ERK signaling, MEK inhibition, combination therapy, apoptosis, cell cycle
- MeSH terms
- Dose-Response Relationship, Drug, Humans, Indoles, Melanoma, Mutation, Sulfonamides, Time Factors, Signal Transduction, Apoptosis, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. https://app.cochat.ai/papers/10.1038/sj.bjc.6605714
- The paper
- Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.